Background: Methods developed to estimate intervention effects in external target populations assume that all important effect measure modifiers have been identified and appropriately modeled. Propensity score-based diagnostics can be used to assess the plausibility of these assumptions for weighting methods.
L
arge randomized controlled trials (RCTs) are designed to generate internally valid estimates of treatment effects. 1 However, this design does not guarantee that the estimated treatment effect will be externally valid in populations of interest because the sampled populations may not represent the target populations. 2, 3 Methods for obtaining treatment effects from an RCT (or other studied population) that are externally valid in specific target populations seek to generate realistic intervention effect estimates that can be used to inform policies targeted at the population level. [4] [5] [6] [7] Propensity score-based weighting methods have been developed to estimate these externally valid treatment effects in specified target populations. 2, 8, 9 In addition to assumptions of external consistency (i.e., the same intervention is applied in the target and study population) and external positivity (i.e., that there was a nonzero probability for being enrolled in the trial for every covariate pattern), weighting methods assume that all patient factors associated with trial participation that modify treatment effects are included and correctly specified in the model being used. Fortunately, it is possible to check these assumptions if treatment and outcome data in the target population under study are available as shown with control arm comparisons in the field of education policy.
Such comparisons could be especially useful in the field of oncology, where external validity of RCT findings is an important concern. In general, enrollment onto cancer trials is low, with less than 5% of adult cancer patients participating. 12, 13 Trial participation is a complex function of clinical and structural factors, a physician's views of a patient's fitness and equipoise, and a patient's willingness to enroll and be randomized. As a result, cancer treatment trials tend to underrepresent certain subgroups of patients, including older adults (age 65+ years), women, racial minorities, and those with lower socioeconomic status. 14 If any of these variables are associated with the outcome, any non-null treatment effects estimated in a trial are unlikely to be generalizable to the clinical practice setting, either on the relative or absolute scale. 15, 16 Historically, assessment of the external validity of cancer treatment trials and other RCT results to target populations has involved the qualitative assessment of differences in patient characteristics among those enrolled in trials and those observed in routine care settings or simply comparing the proportions of individuals with certain demographic characteristics in trials to demographics in clinical practice settings. [17] [18] [19] [20] [21] [22] [23] Increasingly, however, researchers are taking a more quantitative approach to evaluating external validity by comparing the estimated treatment effects from observational cancer cohorts to those in trials. 24 Others have directly compared outcomes from observational cohorts to those reported in trial populations undergoing the same treatment without accounting for differences in patient characteristics between the observational and trial patient populations. 25 Here, we demonstrate a different approach to evaluate assumptions for external validity using data from a phase III trial of chemotherapy for metastatic colorectal cancer by comparing all-cause mortality in the trial control arm (representing the current standard of care) to that of similarly treated patients in routine care using propensity score weighting methods as a diagnostic tool, as introduced by Stuart et al. 10, 11 
METHODS

Data Sources and Study Populations
We obtained RCT data from Project Data Sphere. TM Project Data Sphere TM is an independent, not-for-profit initiative that serves as an online digital library of deidentified data from a variety of trials in cancer. 26 Data are cleaned and stored as SAS datasets with comprehensive data dictionaries and are freely accessible for download by interested researchers.
Project Data Sphere TM provided control arm data from a phase III trial of oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) plus Bevacizumab or Cediranib as First-Line Treatment of Patients with Metastatic Colorectal Cancer (HORIZON III). 27 HORIZON III was a multicenter international trial enrolling patients from Europe, Africa, Asia, and North America. Patients eligible for the trial were 18 years of age or older and were randomly assigned to receive FOLFOX with either (1) bevacizumab or (2) cediranib. Our analyses were restricted to the 257 older adults (age 65+ years) randomized to the control arm (FOLFOX+bevacizumab), as this treatment currently represents the standard of care for metastatic colorectal cancer and we were interested in older adults as the target population. While this trial did not demonstrate a treatment effect for cediranib, the fact that data from the bevacizumab arm are freely available makes it useful for demonstration of these methods.
Data for the target population were derived from a linkage of data from cancer registries included in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program and Medicare enrollment and claims data. SEER collects demographic and tumor data for individuals diagnosed with cancer residing within one of the 18 SEER regions and the linkage with Medicare enrollment and claims data allows for the identification of cancer treatments and follow-up for mortality. 28 The project was approved by the University of North Carolina at Chapel Hill's Institutional Review Board and funded by a grant from the University of North Carolina Lineberger Comprehensive Cancer Center.
The target population was defined based on modified HORIZON III trial inclusion/exclusion criteria. We identified patients 65 years of age or older at diagnosis of a first, primary metastatic colorectal cancer between 2004 and 2011. All patients were required to have continuous Medicare Parts A and B coverage and no managed care enrollment 12 months before and 6 months after their month of diagnosis to ensure capture of important covariates and initial receipt of chemotherapy. Patients were required to initiate first-line chemotherapy with bevacizumab and oxaliplatin within 6 months from the cancer diagnosis (set to the first date of the month of diagnosis). Because oxaliplatin is always coadministered with 5-fluorouracil, we did not require claims for 5-fluorouracil to define FOLFOX. 29 eAppendix A (http://links.lww.com/EDE/ B413) includes the Healthcare Common Procedure Coding System (HCPCS) codes recorded on physician and outpatient claims used to define specific chemotherapeutic agents.
The HORIZON III trial excluded participants with an Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance status greater than 2. As ECOG performance status is not collected in SEER-Medicare data, we attempted to identify a subcohort of the target population who would meet this criteria using two different claimsbased algorithms, the Faurot frailty score 30 and the Davidoff disability status score. 31 We explored various cut-points for identifying individuals likely to be frail or disabled based on predicted probabilities from these algorithms (i.e., >5%, >7.5%, >10%, >11.5%, and >15%).
We built our model estimating the probability of "sampling" or representation in the HORIZON III trial from the potential effect measure modifiers studied in the trial, as well as variables we expected to be associated with the outcome based on literature review and expert opinion. [12] [13] [14] The factors included in our model were participant age (modeled as a quadratic restricted spline with four knots at the 20th, 40th, 60th, and 80th percentiles), cancer site (colon vs. rectum), sex, and tumor differentiation (poor vs. moderate or well differentiated). Age at the start of study follow-up was based on randomization date in the trial and birth date and date of chemotherapy initiation in the target population. In the target population, all covariates were obtained from the cancer registry data. We focused on a complete case analysis for the purposes of this methodologic example because of the small size of the trial population.
All-cause Mortality
In the HORIZON III trial, patients were followed from randomization; survival was defined as time from first treatment with bevacizumab until time of death or end of study, and all-cause mortality was defined as the complement of survival. In the target population, vital status through 31 December 2013 was derived from the Medicare enrollment files with overall survival defined as time from first claim for bevacizumab until date of death and all-cause mortality again defined as its complement.
Statistical Analysis
First, we transferred the HORIZON III trial data onto a secure server containing the linked SEER-Medicare data. We harmonized all study variables and stacked the trial and the target population data into one dataset. We ran multivariable logistic regression models to calculate each individual's probability of being in the HORIZON III trial conditional on the covariates specified above, analogous to a propensity score. 2, 32 We described the propensity score distribution for trial participation in both the trial and target population as a quantitative measure of population overlap. The greater the difference in mean propensity score between the two populations, the greater the difference with respect to the variables in the propensity score model. A difference in propensity score means of >0.25 SD between the trial and target populations indicates a large amount of extrapolation and heavy reliance on sampling models. 10 We also examined propensity score distributions visualized as a density plot to augment this simple summary measure.
Next, we used the propensity score to calculate sampling weights for the trial population. We used inverse odds of sampling weights as discussed by Westreich et al. 2 to assess transportability (i.e., our target population does not include the sampled population). This method can also be used with the inverse probability of sampling weights described by Cole and Stuart 8 and Stuart et al. 11 to assess generalizability when the target population includes the sampled population. These inverse odds of sampling weights are calculated only for trial participants and create a pseudo-trial population that reflects the distribution in the target population of covariates included in the sampling model. We computed weights for each participant in the HORIZON III control arm as the inverse odds of being sampled into the trial from the SEER-Medicare population multiplied by the marginal odds of trial sampling.
This results in a mean weight of approximately one and a weighted HORIZON III trial population similar to the SEERMedicare population sample with respect to the selected covariates. Models included all two-way interactions between each covariate.
We then compared all-cause mortality among the older HORIZON III control arm participants to that of the SEERMedicare target population before and after applying IOSWs. We used the Nelson-Aalen estimator for cumulative hazards, a Kaplan-Meier analogue that better incorporates weights, to plot survival curves for: (1) the unweighted HORIZON III control arm population, (2) the SEER-Medicare target population, and (3) the weighted HORIZON III control arm population for visual comparison. We used Cox proportional hazards models with sandwich covariance estimators to quantitatively compare the survival curves, assessing the proportional hazards assumption by including an interaction term with log-time in the Cox proportional hazards model. Violations of the proportional hazards assumption would mean agreement between the trial and target varied over time. We calculated risk differences (RDs) in all-cause mortality at 6, 12, and 24 months to examine similarity of all-cause mortality at specific time points with bootstrapped 95% confidence intervals (CI), estimated based on the standard deviation of 1,000 bootstrapped replicates from the trial and target populations. The two populations were bootstrapped separately, with resampling with replacement before restricting to individuals with data on tumor differentiation. If the HRs or RDs estimates comparing all-cause mortality in the trial and target populations differed from the null value after applying the inverse odds of sampling weights, then any non-null treatment effect observed in the weighted trial would be biased in the target population. This bias might be present on only the relative scale, only the absolute scale, or on both scales. 16 While small differences could be explained by variation in sampling, the larger the difference, the greater the possible bias. We repeated analyses targeting SEER-Medicare populations below each frailty cutpoint examined. All analyses were performed in SAS 9.3 (Cary, NC) for Windows.
Sensitivity Analyses
We performed sensitivity analyses using a sampling model that excluded variables empirically unassociated with the outcome under the assumption that they could not modify treatment effects and could amplify existing bias when conditioned upon. 32 We assessed the impact of using inverse probability of censoring weights evaluated at the quartiles of drop-out times within the trial and based on the selected covariates to deal with loss to follow-up over time, ensuring the two populations remained comparable. Because mortality ascertainment was complete for SEER-Medicare patients, these weights were only needed in the trial population. Finally, we assessed the impact of truncating inverse odds of sampling weights at the 95th percentile.
RESULTS
There were 690 patients randomized to the control arm in HORIZON III. Of the 257 patients over 65 years old, 18 (7%) were missing data for tumor differentiation, resulting in a final trial population of 232 patients. Of the 2,335 patients meeting inclusion criteria for the SEER-Medicare target population, 393 (17%) were missing data for tumor differentiation, resulting in a final target population of 1,942 patients ( Figure 1 ). eTable 1 (http://links.lww.com/EDE/ B413) describes marginal distributions of modifiers in the cohort before and after restricting to complete case populations, which were similar, though some limited differences were observed with respect to type of cancer where the absolute standardized mean difference between missing and nonmissing patients was 0.10.
Trial and target populations differed substantially with respect to demographic and clinical variables. Table 1 reports the characteristics of the two populations. The median age for trial participants was 70 (interquartile range [IQR]: 67 and 73 years). In contrast, the target population had a median age of 72 (IQR: 69 and 77 years). In total, 44% of the trial population was 65-69 compared with 30% of the SEER-Medicare population. Thirty-one percent of the trial population had rectal rather than colon cancer compared with only 21% of the SEER-Medicare population. Sixty-three percent of the trial population was male compared with 54% of the SEER-Medicare population.
Odds ratio estimates for the full model used to generate propensity scores and inverse odds of sampling weights are listed in eTable 2 (http://links.lww.com/EDE/B413). As expected, the estimated mean probability of sampling (i.e., being represented in the trial) was higher for trial participants at 15.2% than SEER-Medicare patients at 10.1% (difference in mean sampling probability = 5.1%, standardized difference = 0.48). This difference suggests that the trial population is not a random sample of the SEER-Medicare target population with respect to the covariates in the propensity score model. Thus, the trial treatment effects may not be directly extrapolated to the target population if the variables are associated with the outcome. This concern is bolstered by the kernel density plot of propensity scores in Figure 2 , showing substantial differences between the two populations. This plot indicates that there are individuals in the trial population corresponding to all the propensity scores in the target population. One individual had a weight of 12.8, but all other weights were below 5. There was some extrapolation with respect to age as a continuous variable (maximum age 92 in the SEER-Medicare and 89 in HORIZON III).
The weighted trial population was similar to the SEERMedicare target population in marginal distributions of the variables used in the propensity score model with no proportions varying by greater than 1%. Absolute standardized mean differences were well under 0.10. 33 Restricting the target population to patients with a predicted probability of frailty or disability less than 7.5% to mimic the ECOG trial exclusion did not result in large changes in marginal distributions of any covariates. This restriction removed 237 individuals from the target population and resulted in a small downward shift in age and the proportion of women included alongside a small decrease in absolute standardized mean difference for age (Table 2) . Numbers excluded for other frailty thresholds are listed in eTable 3 (http://links.lww.com/EDE/B413). We present the full and <7.5% cohort restricted results because the 236 additional patients excluded with a <5% frailty cutoff resulted in substantial decrease to the target population. Figure 3A shows the survival curves for patients in the full SEER-Medicare population, the unweighted HORIZON III control arm, and the inverse odds of sampling weighted HORIZON III trial control arm. Figure 3B shows analogous survival curves after restricting to the SEER-Medicare population based on a claims-based frailty probability of <7.5%. The trial control arm survival curves were much closer to the SEER-Medicare survival curves after weighting (full cohort trial vs. target weighted HR = 0.96, 95% CI = 0.73, 1.26, frailty-restricted trial vs. target weighted HR = 1.01, 95% CI = 0.78, 1.30), than before (trial vs. target HR = 0.72, 95% CI = 0.58, 0.89, and trial vs. target HR = 0.76, 95% CI = 0.61, 0.94, respectively), especially after the first year of follow-up.
We evaluated the proportional hazards assumption by adding an interaction term between population and log-time (α = 0.20), yielding P = 0.02 for the term in unrestricted unweighted analysis and P = 0.15 for the unrestricted weighted analysis. This result led us to reject the hypothesis of proportional hazards. Violation of the proportional hazards assumption was clear when analyses of the time-specific risks showed the weighting performed better at some time points than others. Table 3 reports the number of events and differences in all-cause mortality at 6, 12, and 24 months between the trial and target populations. While the 6-month (eTable 4; http://links.lww.com/EDE/B413), suggesting the restricted target population was more similar to the trial population, as expected.
Sensitivity Analyses
eTable 5 (http://links.lww.com/EDE/B413) presents results of the multivariable Cox proportional hazards regression of age, sex, tumor differentiation, and type of cancer on mortality. While age and tumor differentiation were strong independent predictors of mortality, type of cancer and sex were not. As a result, we conducted sensitivity analyses excluding type of cancer and sex from the estimation of inverse odds of sampling weights. This resulted in slight shifts of the weighted HR and RDs away from the null. Truncating the 11 individuals with high propensity score weights at the 95th percentile (inverse odds of sampling weight = 2.33) resulted in large shifts away from the null. Applying inverse probability of censoring weights did not substantially change results. Table 4 presents quantitative results of all sensitivity analyses.
DISCUSSION
Using propensity score-based diagnostics to assess external validity can address concerns regarding estimation of treatment effects in specific target populations. In our example, we observed marked heterogeneity in several key risk factors, much like recent studies in substance use disorder treatment using similar methods. 34, 35 Fortunately, the weighted survival curves in the trial control population were much closer to those observed in the target population than the unweighted trial control arm population. By using propensity score models and inverse odds of sampling weights based on age, sex, tumor differentiation, and type of metastatic cancer, we were able to show the HORIZON III trial could be weighted to reflect all-cause mortality observed in the SEER-Medicare target population after 1 year. This result suggests that had the trial reported a non-null treatment effect for cediranib, these factors ought to have been included when transporting from the HORIZON III trial to target populations similar to SEER-Medicare.
We noted interesting residual differences between the weighted trial and SEER-Medicare populations during the first year of follow-up that weighting and frailty restriction did not ameliorate. In the oncologic setting, these kinds of differences may be the result of more intensive monitoring and protocol directed treatment in the trial population relative to the routine care target population, creating a violation of the consistency assumption. 36 Additional baseline variables better predicting duration and completion of treatment or more sophisticated modeling techniques would need to be incorporated if this were the case, as this method cannot distinguish between violations of consistency and exchangeability.
The weighted trial population and SEER-Medicare survival curves came together around 1 year, during which time most patients were likely off protocol directed treatment (due to disease progression); this may reflect differential use of secondline chemotherapy between the weighted and unweighted trial populations. These differences could also be attributable to difficulties excluding patients with very low life expectancies using claims data rather than the detailed in-person clinical evaluations used in cancer treatment trials. Regardless of the reasons for these differences, they increase uncertainty about transporting shorter-term treatment effects from trials with low early mortality to SEER-Medicare populations. Both the present example and the propensity scorebased diagnostics have limitations. The SEER-Medicare data lacked some of the variables used as exclusion criteria in the HORIZON III trial, particularly ECOG status and estimated life expectancy. To counter this deficiency, we explored the impact of restricting to less frail individuals. This slightly improved the performance of the sampling model, though the gap at 6 months remained largely unchanged. We were also missing some data on tumor differentiation in both the trial and target populations. Our complete case analysis excluded individuals with missing data on tumor differentiation, resulting in reduced precision in our estimates and evaluation of transportability in a population with a potentially different covariate distribution than the target population defined by our inclusion criteria. Implementing multiple imputation or weighting methods possible in larger datasets would help ensure we are assessing transportability to the correct target population provided the methods are also implemented in the transport of the trial estimates. 37 Another limitation of the analysis is that we relied on expert advice to identify key covariates for the sampling model; adaptive matching or high dimensional variable selection might perform better in creating sampling models, though it may be difficult to harmonize the amounts of variables necessary to use these techniques. 38 The general concept of comparing weighted and unweighted outcomes would apply regardless of model selection method, however. We also relied on straightforward sampling models, though doubly robust methods incorporating outcome modeling in addition to sampling weighting techniques are also being developed. 9, 39, 40 For these doubly robust estimation techniques, only one of the models used needs to be correctly specified. 2, 9, 41, 42 This approach could be adapted to assess the performance of both components of the doubly robust estimator.
Additional assumptions and limitations are inherent in the method itself. First, it assumes external positivity. Thus, these methods cannot be used to transport treatment effects to populations who would have been ineligible for the trial. We can also only use this method to assess external validity in populations where we have outcome data in routine clinical practice (e.g., after receiving Food and Drug Administration approval). Furthermore, this is primarily a method to "rule-out" inadequacy of the sampling model with respect to meeting the assumptions necessary for external validity. Unfortunately, we cannot say with certainty that the sampling model chosen was the correct one because the effects of unmeasured factors on the outcome could cancel one another out in our target population.
Conclusions
The results of these analyses suggest that the direct transport of both the absolute and relative effects of bevacizumab-based treatment on mortality observed in the HORIZON III trial would likely be invalid for a contemporary target population of older adults except in the absence of treatment effect. A sampling model that weighted the HORIZON III trial population to reflect the age, sex, cancer site, and tumor differentiation of the SEER-Medicare target population appeared more appropriate for the transport of long-term effects on mortality. The method presented here represents a useful tool to identify situations in which researchers should be cautious about external validity of treatment effect estimates from RCTs in target populations of interest. Epidemiologists, trialists, and regulators should explore the use of these tools when predicting the effects of treatment for patients in routine care settings.
